Astellas Pharma Revenue 2012-2019 | ALPMY

Astellas Pharma annual/quarterly revenue history and growth rate from 2012 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Astellas Pharma revenue for the quarter ending December 31, 2019 was $M, a 100% decline year-over-year.
  • Astellas Pharma revenue for the twelve months ending December 31, 2019 was $8.971B, a 25.07% decline year-over-year.
  • Astellas Pharma annual revenue for 2020 was $11.968B, a 1.69% increase from 2019.
  • Astellas Pharma annual revenue for 2019 was $11.769B, a 4.06% decline from 2018.
  • Astellas Pharma annual revenue for 2018 was $12.267B, a 4.75% increase from 2017.
Astellas Pharma Annual Revenue
(Millions of US $)
2020 $11,968
2019 $11,769
2018 $12,267
2017 $11,711
2016 $11,393
2015 $11,350
2014 $11,067
2013 $10,698
2012 $11,822
2011 $11,791
2010 $10,519
2009 $9,947
2008 $9,395
2007 $7,650
2006 $7,993
Astellas Pharma Quarterly Revenue
(Millions of US $)
2019-12-31
2019-06-30 $3,041
2018-06-30 $3,028
2017-06-30 $2,903
2016-09-30 $3,076
2016-06-30 $3,141
2016-03-31 $2,655
2015-12-31 $3,101
2015-09-30 $2,819
2015-06-30 $2,818
2015-03-31 $2,431
2014-12-31 $3,153
2014-09-30 $2,873
2014-06-30 $2,893
2014-03-31
2013-12-31
2013-09-30
2013-06-30 $2,786
2013-03-31
2012-12-31
2012-09-30
2012-06-30 $3,040
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $29.044B $11.967B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $75.491B 42.94
Takeda Pharmaceutical (TAK) Japan $57.222B 9.97
Eisai (ESALY) Japan $25.804B 21.81
UCB SA (UCBJF) Belgium $24.702B 0.00
Merck (MKGAF) Germany $17.189B 0.00
Catalent (CTLT) United States $13.657B 52.80
Grifols, S.A (GRFS) Spain $12.541B 15.33
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $11.140B 0.00
Neurocrine Biosciences (NBIX) United States $10.735B 41.56
Ono Pharmaceutical (OPHLF) Japan $9.254B 16.36
Ionis Pharmaceuticals (IONS) United States $7.852B 49.74
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $7.531B 0.00
Orion OYJ (ORINY) Finland $7.077B 24.56
Jazz Pharmaceuticals (JAZZ) Ireland $6.992B 11.57
STADA ARZNEIMI (STDAF) Germany $6.858B 0.00
United Therapeutics (UTHR) United States $5.009B 11.58
Arrowhead Pharmaceuticals (ARWR) United States $4.115B 0.00
Evotec AG (EVTCY) Germany $4.113B 110.84
FibroGen (FGEN) United States $3.994B 0.00
Hypermarcas (HYPMY) Brazil $3.957B 14.56
Nektar Therapeutics (NKTR) United States $3.889B 0.00
ChemoCentryx (CCXI) United States $3.417B 0.00
PTC Therapeutics (PTCT) United States $3.238B 0.00
Sage Therapeutics (SAGE) United States $2.632B 0.00
Pacira BioSciences (PCRX) United States $2.494B 65.56
Taro Pharmaceutical Industries (TARO) Israel $2.404B 11.64
Cronos Group (CRON) Canada $1.973B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.849B 0.00
Xencor (XNCR) United States $1.840B 0.00
USANA Health Sciences (USNA) United States $1.735B 16.34
Ironwood Pharmaceuticals (IRWD) United States $1.626B 11.33
Corcept Therapeutics (CORT) United States $1.611B 14.83
Indivior (INVVY) United States $1.548B 19.18
Revolution Medicines (RVMD) United States $1.547B 0.00
Akebia Therapeutics (AKBA) United States $1.430B 0.00
Heron Therapeutics (HRTX) United States $1.391B 0.00
Zogenix (ZGNX) United States $1.345B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.320B 12.60
CLINIGEN GP (CLIGF) United Kingdom $1.138B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.133B 0.00
Karyopharm Therapeutics (KPTI) United States $1.119B 0.00
Translate Bio (TBIO) United States $1.094B 0.00
Esperion Therapeutics (ESPR) United States $1.049B 0.00
VAXART, INC (VXRT) United States $1.004B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.943B 589.50
Tilray (TLRY) Canada $0.931B 0.00
Altimmune (ALT) United States $0.876B 0.00
Endo (ENDP) Ireland $0.779B 1.15
Vectura Group (VEGPF) United Kingdom $0.737B 0.00
ImmunoGen (IMGN) United States $0.708B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.700B 0.00
Trillium Therapeutics (TRIL) Canada $0.699B 0.00
Collegium Pharmaceutical (COLL) United States $0.633B 0.00
Flexion Therapeutics (FLXN) United States $0.608B 0.00
Siga Technologies (SIGA) United States $0.600B 64.00
Aerie Pharmaceuticals (AERI) United States $0.586B 0.00
Radius Health (RDUS) United States $0.557B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.540B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.530B 0.00
Molecular Templates (MTEM) United States $0.527B 0.00
Ardelyx (ARDX) United States $0.515B 0.00
Innate Pharma SA (IPHYF) France $0.489B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.481B 18.78
DURECT (DRRX) United States $0.467B 0.00
TherapeuticsMD (TXMD) United States $0.454B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.448B 0.00
Ocular Therapeutix (OCUL) United States $0.438B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.436B 0.00
Organogenesis Holdings (ORGO) United States $0.427B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.419B 10.13
Heat Biologics (HTBX) United States $0.370B 0.00
Calithera Biosciences (CALA) United States $0.318B 0.00
Harpoon Therapeutics (HARP) United States $0.316B 0.00
IMV INC (IMV) Canada $0.315B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.313B 0.00
Redhill Biopharma (RDHL) Israel $0.309B 0.00
OptiNose (OPTN) United States $0.305B 0.00
Rafael Holdings (RFL) United States $0.299B 0.00
MEI Pharma (MEIP) United States $0.295B 0.00
PROFOUND MEDICL (PROF) Canada $0.294B 0.00
Concert Pharmaceuticals (CNCE) United States $0.293B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.269B 0.00
Lannett Co Inc (LCI) United States $0.251B 5.51
CASI Pharmaceuticals (CASI) United States $0.229B 0.00
Aquestive Therapeutics (AQST) United States $0.211B 0.00
Nature's Sunshine Products (NATR) United States $0.210B 20.65
KalVista Pharmaceuticals (KALV) United States $0.207B 0.00
Nivalis Therapeutics (ALPN) United States $0.197B 0.00
Taiwan Liposome (TLC) Taiwan $0.195B 0.00
Onconova Therapeutics (ONTX) United States $0.192B 0.00
Jounce Therapeutics (JNCE) United States $0.163B 7.74
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.137B 0.00
Xeris Pharmaceuticals (XERS) United States $0.126B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.117B 0.00
Addex Therapeutics (ADXN) Switzerland $0.115B 0.00
Champions Oncology (CSBR) United States $0.114B 0.00
Otonomy (OTIC) United States $0.110B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.107B 0.00
MediWound (MDWD) Israel $0.106B 0.00
Recro Pharma (REPH) United States $0.104B 0.00
Biomerica (BMRA) United States $0.104B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.103B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.100B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.098B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.098B 0.00
CTI BioPharma (CTIC) United States $0.092B 0.00
Lipocine (LPCN) United States $0.088B 0.00
Aclaris Therapeutics (ACRS) United States $0.088B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.087B 0.00
ElectroCore (ECOR) United States $0.085B 0.00
SCYNEXIS (SCYX) United States $0.069B 0.00
CV Sciences (CVSI) United States $0.065B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.064B 0.00
PolarityTE (PTE) United States $0.059B 0.00
Sundial Growers (SNDL) Canada $0.058B 0.00
Infinity Pharmaceuticals (INFI) United States $0.058B 0.00
GTx (ONCT) United States $0.056B 0.00
RENEURON GP (RNUGF) United Kingdom $0.053B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 30.73
Novan (NOVN) United States $0.051B 0.00
Natural Alternatives (NAII) United States $0.047B 0.00
Forward Pharma (FWP) Denmark $0.046B 0.00
Jaguar Animal Health (JAGX) United States $0.044B 0.00
Mannatechorporated (MTEX) United States $0.044B 8.26
Entasis Therapeutics Holdings (ETTX) United States $0.042B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.039B 0.00
Neos Therapeutics (NEOS) United States $0.036B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.036B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.029B 0.00
Iterum Therapeutics (ITRM) Ireland $0.022B 0.00
Vical (BBI) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.019B 0.00
Bio-Path Holdings (BPTH) United States $0.018B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.018B 0.00
RXi Pharmaceuticals (PHIO) United States $0.016B 0.00
Flex Pharma (SLRX) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.015B 34.77
Shineco (TYHT) China $0.014B 0.00
China SXT Pharmaceuticals (SXTC) China $0.014B 0.00
Midatech Pharma (MTP) United Kingdom $0.013B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.013B 0.00
HANCOCK JAFFE (HJLI) United States $0.009B 0.00
Xenetic Biosciences (XBIO) United States $0.008B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00